abstract |
A pharmaceutical composition comprising (a) an SGLT2 inhibitor, and (b) a GLP-1 receptor agonist, without a third antidiabetic agent, wherein the SGLT2 inhibitor is 1-chloro-4- (β-D -glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) -benzyl] -benzene and in which the amount of the SGLT2 inhibitor is 1 to 25 mg. |